- Home
- LRHC vs CANF Comparison
LRHC vs CANF Comparison
Compare LRHC & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LRHC | CANF |
|---|---|---|
| Founded | 2004 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 2.9M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | LRHC | CANF |
|---|---|---|
| Price | $0.69 | $0.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.25 |
| AVG Volume (30 Days) | 294.0K | ★ 10.1M |
| Earning Date | 11-19-2025 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $78,660,186.00 | $560,000.00 |
| Revenue This Year | N/A | $461.72 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.52 | N/A |
| 52 Week Low | $0.63 | $0.17 |
| 52 Week High | $95.20 | $2.33 |
Technical Indicators
Market Signals| Indicator | LRHC | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 20.85 | 35.80 |
| Support Level | $0.63 | $0.17 |
| Resistance Level | $0.75 | $0.20 |
| Average True Range (ATR) | 0.12 | 0.03 |
| MACD | 0.10 | -0.00 |
| Stochastic Oscillator | 4.36 | 22.17 |
Price Performance
Historical ComparisonAbout LRHC La Rosa Holdings Corp.
La Rosa Holdings Corp operates in the U.S. residential real estate market. It is a holding company for agent-centric, technology-integrated, cloud-based, multi-service real estate companies. The company's business is organized based on the services it provides internally to the agents and to the public, which are residential and commercial real estate brokerage, franchising, real estate brokerage education and coaching, and property management. The company has six reportable segments, namely: Real Estate Brokerage Services (Residential), Franchising Services, Coaching Services, Property Management, Real Estate Brokerage Services (Commercial), and Title Settlement and Insurance. It derives maximum revenue from the Real Estate Brokerage Services (Residential) segment.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).